Verastem Says FDA Agreed To Make Survival A Secondary Goal In Pancreatic Cancer Trial

Verastem's development chief says regulators also allowed response rate as a dual primary endpoint, which could open an accelerated-approval route.

Share
Verastem Says FDA Agreed To Make Survival A Secondary Goal In Pancreatic Cancer Trial

Verastem Oncology, which develops cancer medicines aimed at RAS/MAPK-driven tumors, said on its third-quarter earnings call Thursday that the FDA agreed to make overall survival a secondary endpoint in its first-line pancreatic cancer trial. Michael Kauffman, the company's President of Development, said that as far as Verastem is aware, it is "for the first time ever" for a randomized phase 3 trial seeking approval in frontline pancreatic cancer, as net product revenue of $24 million for the quarter took a back seat.

Why survival moved down

The trial, called Target D301, has three arms with one-to-one-to-one randomization. Two-thirds of patients get the company's drug VS-7375 upfront, and one-third get standard chemotherapy. Chemotherapy patients can cross over to VS-7375 once independently reviewed CT scans show progression.

Because everyone can end up on the drug, Kauffman said, the study becomes essentially VS-7375 in the front line versus the second line. That "confuses the endpoint," he said, and he said the FDA agreed with the logic.

The agency also allowed overall response rate as a dual primary endpoint alongside progression-free survival. Kauffman said Verastem has no explicit agreement that the FDA will grant accelerated approval on response rate, but that the FDA's Front Runner Program could offer a route. Response rate would mature before progression-free survival, he said.

Why the FDA went along

A BTIG analyst asked why the agency accepted this design when rival Insight is pursuing progression-free and overall survival as co-primary endpoints. CEO Dan Paterson credited the agency's cooperation to the drug's tolerability and efficacy. "I don't want to say you get cut a break," he said, adding that regulators weigh risk and benefit to patients.

Kauffman pointed to a 50% confirmed response rate for VS-7375 in second-line pancreatic cancer, against 24% he attributed to a rival drug, daraxonrasib, in KRAS G12D tumors.

Money and timing

Verastem expects to open Target D301 by the end of 2026. Kauffman said such phase 3 trials typically run about 100 sites. The company plans to start colorectal and lung phase 3 trials in the first half of 2027, once it aligns with the FDA on protocols.

Paterson said the October raise of about $250 million funds operations into the first half of 2028. Cash and investments stood at $172.8 million at the end of the third quarter, or $422.8 million pro forma with the raise, CFO Dan Calkins said.

The company's marketed product, a combination of avutometinib and defactinib for a rare ovarian cancer, brought in $24 million in the quarter, up 114% from the third quarter of 2025, Calkins said. Paterson also said he will step down as CEO at the end of 2026, with board member Michael Bailey taking over.

Target D301 is the first of three planned frontline phase 3 trials, and Verastem says it expects to open it before the end of 2026.

Sources

More on Verastem

All Verastem (VSTM) coverage →